Aulos Bioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24

blonca9
Jun 2, 2024
1 min read

Updated: Nov 9, 2024

Aron Knickerbocker describes the benefits of focusing on the CD-25 binding portion of IL-2 and discusses some data presented at ASCO. He believes this program is the first AI designed human antibody to enter the clinic.

Recent Posts

See All

After exiting stealth with $20 million two weeks ago, Orchestra Bio is out to help science entrepreneurs handle the dollars and cents management and long term planning that business requires

IO Biotech CEO Mai-Britt Zocca discusses the phase 3 pivotal trial result of the cancer vaccine Cylembio in first line advanced melanoma - and the company's strategy ahead

Visiting Genezen Indianpolis to see where it all started - and where the company today makes lenti and retroviral vectors for cell and gene therapies

Aulos Bioscience CEO Aron Knickerbocker discusses his company's antibody approach to IL-2 at #ASCO24

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight